Research
A GLP-1 Drug Cut Heavy Drinking in a Trial for Alcohol Use Disorder
Altimmune's pemvidutide reduced heavy-drinking days more than placebo in a Phase 2 study — early evidence that GLP-1-class drugs may curb more than appetite.